Ask1 a novel regulator of platelet function

Ask1 一种新型血小板功能调节剂

基本信息

  • 批准号:
    9034654
  • 负责人:
  • 金额:
    $ 39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-02-01 至 2018-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The foremost cause of death in humans is cardiovascular diseases such as myocardial infarction and stroke. Circulating platelets play an important role in the pathogenesis of these diseases. Platelets are anucleated cells with a complex cytoskeletal system, unique receptors, and specialized secretary granules. They are found in the circulation in high abundance, and respond to blood vessel injury by changing shape, secreting granular contents, and aggregation. This is advantageous in the regulation of physiological hemostasis, but can be unfavorable in pathological thrombosis. For this reason, understanding the mechanisms surrounding platelet aggregation is essential. Platelet function is tightly regulated by both pro- and anti-stimulatory mechanisms. Platelets are kept in an unstimulated state by little-known anti-stimulatory mechanisms. During vascular injury, pro-stimulatory mechanisms, such as signaling by various physiological agonists, override the anti-stimulatory machinery to achieve platelet aggregation. We have identified a novel platelet protein, ASK1, which appears to be a key participant in the pro-stimulatory mechanism. We hypothesize that ASK1 senses stress and/or pro-stimulatory signals initiated by agonists and transmits signals to the platelet fibrinogen receptor complex and helps in coordinating stimulatory signals that regulate platelet aggregation and thrombus formation. This proposal is focused on understanding the molecular mechanisms that are regulated by ASK1 in order to regulate platelet activation. The identification and characterization of such regulatory mechanisms may define new targets for developing potential therapeutic agents toward thrombotic disorders.
描述(由申请人提供):人类死亡的首要原因是心血管疾病,如心肌梗死和中风。循环血小板在这些疾病的发病机制中起重要作用。血小板是一种无核细胞,具有复杂的细胞骨架系统、独特的受体和特化的分泌颗粒。它们在循环中大量存在,并通过改变形状、分泌颗粒状内容物和聚集来对血管损伤作出反应。这在生理止血的调节中是有利的,但在病理性血栓形成中可能是不利的。因此,了解血小板聚集的机制至关重要。血小板功能受到促刺激和抗刺激机制的严格调节。血小板通过鲜为人知的抗刺激机制保持在非刺激状态。在血管损伤期间,促刺激机制,例如通过各种生理激动剂的信号传导,超越抗刺激机制以实现血小板聚集。我们已经确定了一种新的血小板蛋白,ASK 1,这似乎是一个关键的参与者在促刺激机制。我们假设ASK 1感知由激动剂引发的应激和/或促刺激信号,并将信号传递给血小板纤维蛋白原受体复合物,并有助于协调调节血小板聚集和血栓形成的刺激信号。该提案的重点是了解由ASK 1调节以调节血小板活化的分子机制。这种调节机制的鉴定和表征可以定义用于开发针对血栓性疾病的潜在治疗剂的新靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ULHAS P NAIK其他文献

ULHAS P NAIK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ULHAS P NAIK', 18)}}的其他基金

Regulation of Platelet Reactivity by S1P Signaling
S1P 信号传导调节血小板反应性
  • 批准号:
    10436813
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
ASK1 a novel regulator of platelet function
ASK1 一种新型血小板功能调节剂
  • 批准号:
    10383745
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
Regulation of Platelet Reactivity by S1P Signaling
S1P 信号传导调节血小板反应性
  • 批准号:
    10183303
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
ASK1 a novel regulator of platelet function
ASK1 一种新型血小板功能调节剂
  • 批准号:
    9899282
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
Ask1 a novel regulator of platelet function
Ask1 一种新型血小板功能调节剂
  • 批准号:
    8605910
  • 财政年份:
    2013
  • 资助金额:
    $ 39万
  • 项目类别:
Endogenous suppression of integrin signaling
整合素信号传导的内源性抑制
  • 批准号:
    9036653
  • 财政年份:
    2013
  • 资助金额:
    $ 39万
  • 项目类别:
Endogenous suppression of integrin signaling
整合素信号传导的内源性抑制
  • 批准号:
    8705582
  • 财政年份:
    2013
  • 资助金额:
    $ 39万
  • 项目类别:
Endogenous suppression of integrin signaling
整合素信号传导的内源性抑制
  • 批准号:
    8561826
  • 财政年份:
    2013
  • 资助金额:
    $ 39万
  • 项目类别:
Endogenous suppression of integrin signaling
整合素信号传导的内源性抑制
  • 批准号:
    10192787
  • 财政年份:
    2013
  • 资助金额:
    $ 39万
  • 项目类别:
Endogenous suppression of integrin signaling
整合素信号传导的内源性抑制
  • 批准号:
    8856656
  • 财政年份:
    2013
  • 资助金额:
    $ 39万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 39万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 39万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 39万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 39万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 39万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 39万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了